Gyre Therapeutics reported Q3 2024 revenues of $25.5 million, down 20% YoY from $32.0 million, with net income of $2.9 million compared to $7.5 million in Q3 2023. The revenue decline was primarily due to decreased anti-fibrosis drug sales amid challenging Chinese economic conditions affecting healthcare spending. Gross profit was $24.5 million with a 96.2% margin.Operating expenses increased 12% YoY to $20.3 million, mainly driven by higher general and administrative costs associated with being a public company. Research and development expenses decreased 8% to $2.8 million as the company advanced key clinical programs, including the completion of F351's Phase 3 trial for liver fibrosis with top-line data expected in Q1 2025.The company maintained a strong financial position with $54.6 million in cash and investments as of September 30, 2024. Management expects to launch two new products - nintedanib and avatrombopag - in early 2025 to support revenue growth. The company also plans to initiate a Phase 2 trial of F351 for MASH-associated liver fibrosis in the US in 2025, pending IND approval.

Gyre Therapeutics reported Q3 2024 revenues of $25.5 million, down 20% YoY from $32.0 million, with net income of $2.9 million compared to $7.5 million in Q3 2023. The revenue decline was primarily due to decreased anti-fibrosis drug sales amid challenging Chinese economic conditions affecting healthcare spending. Gross profit was $24.5 million with a 96.2% margin.Operating expenses increased 12% YoY to $20.3 million, mainly driven by higher general and administrative costs associated with being a public company. Research and development expenses decreased 8% to $2.8 million as the company advanced key clinical programs, including the completion of F351's Phase 3 trial for liver fibrosis with top-line data expected in Q1 2025.The company maintained a strong financial position with $54.6 million in cash and investments as of September 30, 2024. Management expects to launch two new products - nintedanib and avatrombopag - in early 2025 to support revenue growth. The company also plans to initiate a Phase 2 trial of F351 for MASH-associated liver fibrosis in the US in 2025, pending IND approval.